Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 1047-1056

  Grube, Matthias ^a   Rezvani, Katayoun ^a   Wiestner, Adrian ^b   Fujiwara, Hiroshi ^a   Sconocchia, Giuseppe ^a   Melenhorst, Jan J ^a   Hensel, Nancy ^a   Marti, Gerald E ^c   Kwak, Larry W ^b   Wilson, Wyndham ^b   Barrett, John A ^a,d  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUDARABINE; GAMMA INTERFERON; HLA ANTIGEN; MESSENGER RNA; PREDNISONE; RNA; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL INTERACTION; CELL SPECIFICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG POTENCY; EPITOPE MAPPING; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD40; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DNA, COMPLEMENTARY; FEMALE; FLOW CYTOMETRY; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PEPTIDES; POLYMERASE CHAIN REACTION; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC;

EID: 10744225702     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0075     Document Type: Article

References (65)

1. Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity, 10: 281-287, 1999.
2. Brandle, D., Brasseur, F., Weynants, P., Boon, T., and Van den, E. B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med., 183: 2501-2508, 1996.
3. Gueguen, M., Patard, J. J., Gaugler, B., Brasseur, F., Renauld, J. C., Van Cangh, P. J., Boon, T., and Van den Eynde, B. J. An antigen recognized by autologous CTLs on a human bladder carcinoma. J. Immunol., 160: 6188-6194, 1998.
4. Yi, Q., Eriksson, I., He, W., Holm, G., Mellstedt, H., and Osterborg, A. Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. Br. J. Haematol., 96: 338-345, 1997.
5. Rezvany, M. R., Jeddi-Tehrani, M., Rabbani, H., Lewin, N., Avila-Carino, J., Osterborg, A., Wigzell, H., and Mellstedt, H. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. Br. J. Haematol., 111: 608-617, 2000.
6. Gitelson, E., Hammond, C., Mena, J., Lorenzo, M., Buckstein, R., Berinstein, N. L., Imrie, K., and Spaner, D. E. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin. Cancer Res., 9: 1656-1665, 2003.
7. Shinohara, N., Watanabe, M., Sachs, D. H., and Hozumi, N. Killing of antigen-reactive B cells by class II-restricted, soluble antigen-specific CD8+ cytolytic T lymphocytes. Nature (Lond), 336: 481-484, 1988.
8. Osterborg, A., Yi, Q., Bergenbrant, S., Holm, G., Lefvert, A. K., and Mellstedt, H. Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br. J. Haematol., 89: 110-116, 1995.
9. Rasmussen, T., Hansson, L., Osterborg, A., Johnsen, H. E., and Mellstedt, H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood, 101: 4607-4610, 2003.
10. Li, Y., Bendandi, M., Deng, Y., Dunbar, C., Munshi, N., Jagannath, S., Kwak, L. W., and Lyerly, H. K. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood, 96: 2828-2833, 2000.
11. Ruffini, P. A., Neelapu, S. S., Kwak, L. W., and Biragyn, A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica, 87: 989-1001, 2002.
12. Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., Jaffe, E. S., Creekmore, S. P., Longo, D. L., and Kwak, L. W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med., 5: 1171-1177, 1999.
13. Coulie, P. G. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol. Med. Today, 3: 261-268, 1997.
14. De Visser, K. E., Schumacher, T. N., and Kruisbeek, A. M. CD8+ T cell tolerance and cancer immunotherapy. J. Immunother., 26: 1-11, 2003.
15. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature (Lond), 411: 380-384, 2001.
16. Kappler, J. W., Roehm, N., and Marrack, P. T cell tolerance by clonal elimination in the thymus. Cell, 49: 273-280, 1987.
17. Kisielow, P., Bluthmann, H., Staerz, U. D., Steinmetz, M., and von Boehmer, H. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature (Lond), 333: 742-746, 1988.
18. Sha, W. C., Nelson, C. A., Newberry, R. D., Kranz, D. M., Russell, J. H., and Loh, D. Y. Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature (Lond), 336: 73-76, 1988.
19. Pircher, H., Burki, K., Lang, R., Hengartner, H., and Zinkernagel, R. M. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature (Lond), 342: 559-561, 1989.
20. Amsen, D., and Kruisbeek, A. M. Thymocyte selection: not by TCR alone. Immunol. Rev., 165: 209-229, 1998.
21. Stockinger, B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv. Immunol., 71: 229-265, 1999.
22. Vitetta, E. S., Thorpe, P. E., and Uhr, J. W. Immunotoxins: magic bullets or misguided missiles? Immunol. Today, 14: 252-259, 1993.
23. Grossbard, M. L., Press, O. W., Appelbaum, F. R., Bernstein, I. D., and Nadler, L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood, 80: 863-878, 1992.
24. Waldmann, T. A. Monoclonal antibodies in diagnosis and therapy. Science (Wash. DC), 252: 1657-1662, 1991.
25. Maloney, D. G., Brown, S., Czerwinski, D. K., Liles, T. M., Hart, S. M., Miller, R. A., and Levy, R. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood, 80: 1502-1510, 1992.
26. Dillman, R. O. Antibodies as cytotoxic therapy. J. Clin. Oncol., 12: 1497-1515, 1994.
27. Cooper, L. J., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W. C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., and Jensen, M. C. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood, 101: 1637-1644, 2003.
28. Roessig, C., Scherer, S. P., Baer, A., Vormoor, J., Rooney, C. M., Brenner, M. K., and Juergens, H. Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann. Hematol., 81 (Suppl. 2): S42-S43, 2002.
29. Brentjens, R. J., Latouche, J. B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Riviere, I., and Sadelain, M. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med., 9: 279-286, 2003.
30. Jensen, M., Cooper, L., Wu, A., Forman, S., and Raubitschek, A. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy, 5: 131-138, 2003.
31. Roberts, W. K., Livingston, P. O., Agus, D. B., Pinilla-Ibarz, J., Zelenetz, A., and Scheinberg, D. A. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood, 99: 3748-3755, 2002.
32. Nadler, L. M., Anderson, K. C., Marti, G., Bates, M., Park, E., Daley, J. F., and Schlossman, S. F. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol., 131: 244-250, 1983.
33. Nadler, L. M., Korsmeyer, S. J., Anderson, K. C., Boyd, A. W., Slaughenhoupt, B., Park, E., Jensen, J., Coral, F., Mayer, R. J., Sallan, S. E., et al. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J. Clin. Investig., 74: 332-340, 1984.
34. Tedder, T. F., and Engel, P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today, 15: 450-454, 1994.
35. Campos, L., Guyotat, D., Larese, A., Mazet, L., Bourgeot, J. P., Ehrsam, A., and Fiere, D. Expression of CD 19 antigen on acute monoblastic leukemia cells at diagnosis and after TPA-induced differentiation. Leuk. Res., 12: 369-372, 1988.
36. Tedder, T. F., and Schlossman, S. F. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J. Biol. Chem., 263: 10009-10015, 1988.
37. Zweerink, H. J., Gammon, M. C., Utz, U., Sauma, S. Y., Harrer, T., Hawkins, J. C., Johnson, R. P., Sirotina, A., Hermes, J. D., Walker, B. D., et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol., 150: 1763-1771, 1993.
38. Storkus, W. J., Howell, D. N., Salter, R. D., Dawson, J. R., and Cresswell, P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol., 138: 1657-1659, 1987.
39. Hogan, K. T., Shimojo, N., Walk, S. F., Engelhard, V. H., Maloy, W. L., Coligan, J. E., and Biddison, W. E. Mutations in the α 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide. J. Exp. Med., 168: 725-736, 1988.
40. Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., and Stevanovic, S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics, 50: 213-219, 1999.
41. McIntyre, C. A., Rees, R. C., Platts, K. E., Cooke, C. J., Smith, M. O., Mulcahy, K. A., and Murray, A. K. Identification of peptide epitopes of MAGE-1, -2, -3 that demonstrate HLA-A3-specific binding. Cancer Immunol. Immunother., 42: 246-250, 1996.
42. McArdle, S. E., Rees, R. C., Mulcahy, K. A., Saba, J., McIntyre, C. A., and Murray, A. K. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunol. Immunother., 49: 417-425, 2000.
43. Molldrem, J., Dermime, S., Parker, K., Jiang, Y. Z., Mavroudis, D., Hensel, N., Fukushima, P., and Barrett, A. J. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood, 88: 2450-2457, 1996.
44. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. Real time quantitative PCR. Genome Res., 6: 986-994, 1996.
45. Kruse, N., Pette, M., Toyka, K., and Rieckmann, P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J. Immunol. Methods, 210: 195-203, 1997.
46. Kammula, U. S., Lee, K. H., Riker, A. I., Wang, E., Ohnmacht, G. A., Rosenberg, S. A., and Marincola, F. M. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol., 163: 6867-6875, 1999.
47. Schultze, J. L., Michalak, S., Seamon, M. J., Dranoff, G., Jung, K., Daley, J., Delgado, J. C., Gribben, J. G., and Nadler, L. M. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Investig., 100: 2757-2765, 1997.
48. Jiang, Y. Z., Mavroudis, D., Dermime, S., Hensel, N., Couriel, D., Molldrem, J., and Barrett, A. J. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br. J. Haematol., 93: 606-612, 1996.
49. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood, 102: 2892-2900, 2003.
50. Molldrem, J. J., Lee, P. P., Kant, S., Wieder, E., Jiang, W., Lu, S., Wang, C., and Davis, M. M. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Investig., 111: 639-647, 2003.
51. Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P., and Hodes, R. J. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med., 180: 631-640, 1994.
52. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond), 392: 245-252, 1998.
53. Kwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., Miller, R. A., and Levy, R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med., 327: 1209-1215, 1992.
54. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
55. Krackhardt, A. M., Harig, S., Witzens, M., Broderick, R., Barrett, P., and Gribben, J. G. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood, 100: 167-173, 2002.
56. Kruisbeek, A. M., and Amsen, D. Mechanisms underlying T-cell tolerance. Curr. Opin. Immunol., 8: 233-244, 1996.
57. Sebzda, E., Mariathasan, S., Ohteki, T., Jones, R., Bachmann, M. F., and Ohashi, P. S. Selection of the T cell repertoire. Annu. Rev. Immunol., 17: 829-874, 1999.
58. De Visser, K. E., Cordaro, T. A., Kioussis, D., Haanen, J. B., Schumacher, T. N., and Kruisbeek, A. M. Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur. J. Immunol., 30: 1458-1468, 2000.
59. Miller, J. F., and Morahan, G. Peripheral T cell tolerance. Annu. Rev. Immunol., 10: 51-69, 1992.
60. Targoni, O. S., and Lehmann, P. V. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J. Exp. Med., 187: 2055-2063, 1998.
61. Ranheim, E. A., and Kipps, T. J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med., 177: 925-935, 1993.
62. Yellin, M. J., Sinning, J., Covey, L. R., Sherman, W. Lee, J. J., Glickman-Nir, E., Sippel, K. C., Rogers, J., Cleary, A. M. Parker, M., et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J. Immunol., 153: 666-674, 1994.
63. Van den Hove, L. E., Van Gool, S. W., Vandenberghe, P., Bakkus, M., Thielemans, K., Boogaerts, M. A., and Ceuppens, J.L., CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by upregulation of CD80 and CD86 costimulatory molecules. Leukemia (Baltimore), 11: 572-580, 1997.
64. Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., and Catovsky, D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J. Clin. Pathol., 51: 364-369, 1998.
65. Cabezudo, E., Carrara, P., Morilla, R., and Matutes, E. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica, 84: 413-418, 1999.